Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics Inc LCTX

Healthcare Biotechnology
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and... see more

Recent & Breaking News (NYSEAM:LCTX)

Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron's Embryonic Stem Cell Assets

Business Wire October 1, 2013

BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem® Technology

Business Wire September 19, 2013

BioTime Receives Approval to Begin Human Clinical Trials of Renevia

Business Wire August 28, 2013

BioTime Announces the Appointment of Lesley Stolz as Executive Vice President of Corporate Development

Business Wire August 21, 2013

BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine Conference

Business Wire August 19, 2013

BioTime Announces Second Quarter 2013 Financial Results and Recent Corporate Accomplishments

Business Wire August 9, 2013

PDL BioPharma Announces Second Quarter 2013 Financial Results

PR Newswire August 8, 2013

BioTime's Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker

Business Wire August 5, 2013

BioTime Subsidiary LifeMap Sciences Announces Publication of Research Report Describing LifeMap Discovery(TM)

Business Wire July 18, 2013

BioTime CEO Dr. Michael West to Present at the Case Western Reserve University 6th Annual Regenerative Medicine Business Education Course

Business Wire July 16, 2013

BioTime Appoints Henry L. Nordhoff to Board of Directors

Business Wire June 12, 2013

BioTime, Inc. Closes on $9 Million Financing

Business Wire June 7, 2013

Vista Partners Publishes June 2013 Macroeconomic & Investment Newsletter

Marketwired June 4, 2013

BioTime, Inc. to Raise $9 Million in Registered Direct Offering

Business Wire June 3, 2013

BioTime Announces Results of Vote at Special Meeting of Shareholders

Business Wire May 23, 2013

BioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair

Business Wire May 20, 2013

BioTime Appoints Franklin Berger to Board of Directors

Business Wire May 14, 2013

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel's Office of the Chief Scientist

Business Wire May 13, 2013

BioTime Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments

Business Wire May 10, 2013

PDL BioPharma Announces First Quarter 2013 Financial Results

PR Newswire May 9, 2013